Chiesi Limited, the UK affiliate of Italian healthcare company Chiesi Farmaceutici, has launched a new mobile app for adult patients with asthma or chronic obstructive pulmonary disease (COPD) to support with patient adherence and device technique.
The app, which will be used by healthcare professionals, is specifically catered to those who have been prescribed Chiesi’s Fostair (beclometasone/formoterol) pressurised metered-dose inhaler (pMDI) or dry powder inhaler Fostair NEXThaler.
According to the group, inefficient inhalation technique is a common problem as patients tend to forget to how to use their inhalers appropriately and introducing new errors with time.
Inhaler misuse has been associated with increased risk of hospitalisation, courses of oral steroids and poor disease control.
Patients using Chiesi’s app will be able to review their inhaler technique and can share this during their consultations with their HCPs.
The new app also offers dose reminders and a dose history review to help recognise patterns.
Tom Delahoyde, managing director of Chiesi LTD, said: “Our aim is to help HCPs to better support patients in achieving the desired outcome from their Fostair treatment.
“With this in mind, we have designed an app which aims to support HCPs with patients inhaler technique training.”
The app is available on both Android and Apple operating systems.
